Navigation Links
PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
Date:9/26/2008

e Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; or similar statements are forward-looking statements. PharmAthene disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, the award of government contracts to our competitors, unforeseen safety issues, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, as well as risks detailed from time to time in PharmAthene's Form 10-K under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC"). In particular, just because the DHHS has awarded this contract to the Company for the advanced development of our third generation rPA anthrax vaccine, there can be no assurance that (1) the work under this contract will result in a safe and effective anthrax vaccine approved for use in humans, (2) DHHS will exercise all options under the contract, or (3) DHHS or any other government agencies or departments will ever procure doses of our third generation rPA vaccine for civilian or military purposes. Copies of PharmAthene's public disclosure filings are available from its investor relations department and o
'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. PharmAthene to Present Data for Protexia(R) and Valortim(R) at HHS PHEMCE Stakeholders Workshop 2008
2. PharmAthene to Present at the UBS Global Life Sciences Conference on Thursday September 25, 2008
3. PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration
4. PharmAthene Reports Second Quarter 2008 Financial and Operational Results
5. Lord Lewis Moonie to Serve as Special UK Government Advisor to PharmAthene
6. PharmAthene Appoints Jordan P. Karp, J.D. Senior Vice President and General Counsel
7. PharmAthene Reports First Quarter 2008 Financial Results
8. PharmAthene to Host First Quarter 2008 Conference Call and Webcast on Tuesday, May 13, 2008
9. PharmAthene Closes Acquisition of Avecia Biodefense Vaccines Business Unit
10. PharmAthene Reports Year-End 2007 Financial Results
11. Department of Defense Awards $5.8 Million Contract Modification Providing Additional Funding for PharmAthenes Protexia(R) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Texas , Dec. 16, 2014  Vermillion, Inc. ... focused on gynecologic disease, today announced the next step ... a premier bio-analytics solutions provider with the naming of ... President and Chief Executive Officer, while current Chairman of ... continue to serve as Chairman. These changes are effective ...
(Date:12/17/2014)... 17, 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... acquisition, development and commercialization of innovative therapeutics addressing cancer ... with a primary commercial focus on China ... a Type C meeting with the U.S. Food and ... held in February 2015.  During this meeting the Company ...
(Date:12/17/2014)... 17, 2014   Synageva BioPharma Corp. (NASDAQ: ... products for rare disorders, announced today its presentation at ... San Francisco, CA. ... Officer, will present on Monday, January 12, 2015, at ... be webcast live and may be accessed from the ...
(Date:12/15/2014)... NEW YORK & PETACH TIKVAH, ... Therapeutics Inc. (NASDAQ: BCLI ), a leading ... announced today that wholly-owned subsidiary Brainstorm Cell Therapeutics Ltd. ... Israel,s Office of the Chief ... has been in receipt of grant support from the ...
Breaking Biology Technology:Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3
... TopSpin Medical,(TASE: TOPMD), the developer of a unique ... catheter for the coronary arteries,announced today the appointment ... Dr. Setum has over 15 years of ... She has a Ph.D. from the University of,Minnesota, ...
... PALO ALTO, Calif. and OSAKA, Japan, Oct. 17 ... Pharmaceutical Company Limited (TSE: 4502),today announced that they ... from the Licensing Executives Society of the U.S. ... develop and commercialize,Affymax,s lead product candidate, Hematide(TM), for ...
... transplant patients ... and their caregivers, ... Sheets: ALPMF), a leader in the field of transplantation, and,The ... a collaborative partnership to jointly,develop further materials for the multi-award-winning ...
Cached Biology Technology:TopSpin Medical Appoints Cindy Setum, Ph.D., Vice President Clinical Affairs 2Affymax(R) and Takeda Recognized for Innovative Global Agreement to Develop and Commercialize Hematide(TM) for Anemia 2Affymax(R) and Takeda Recognized for Innovative Global Agreement to Develop and Commercialize Hematide(TM) for Anemia 3Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program 2Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program 3
(Date:12/19/2014)...   LaunchKey , the first decentralized mobile authentication ... of Things era, today announced the close of $3 ... led by Metamorphic Ventures with participation from ENIAC Ventures, ... others.  LaunchKey has raised $4 million to date, and ... and bring LaunchKey to market in 2015. ...
(Date:12/17/2014)... -- Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ... with the clinical data to back it up," said ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ...  report to their offering. One ... in technology. With continuous advances in technology, it ... latest standard that meets the needs and expectations ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... The University of Western Ontario, working in collaboration with ... line to reveal a previously unidentified mechanism contributing to ... Gros and Vania Prado of London, Canada and Silvia ... the neurotransmitter acetylcholine, a chemical messenger which slows cardiac ...
... around the world hasten to employ nanotechnology to ... manufacturing materials to creating new pharmaceutical drugs, a ... has shown that previous industrial revolutions, such as ... serious environmental impacts. Might nanotechnology also pose ...
... This release is available in Spanish . ... scientists are helping to increase understanding about the environmental ... potent antioxidant properties, in oat grain. Avns are ... many health benefits. The specific purpose of Avns inside ...
Cached Biology News:Genetically-modified mice reveal another mechanism contributing to heart failure 2Engineers explore environmental concerns of nanotechnology 2Engineers explore environmental concerns of nanotechnology 3Engineers explore environmental concerns of nanotechnology 4Engineers explore environmental concerns of nanotechnology 5Studies provide insight into key oat chemical 2
... flexible quadrupole MS detector optimized for HPLC ... and 2-D LC, as well as capillary ... drying gas system to create a finer ... low-to-medium polarity compounds, while providing for high ...
... is the ideal CO2 incubator for cell ... or embryos at or near body temperature. ... everything needed to protect and grow your ... stable incubation conditions ensure optimum culture growth. ...
... single-stranded DNA and RNA endonucleolytically to ... (DNA:DNA, DNA:RNA or RNA:RNA) are resistant ... concentrations of enzyme (1). The enzyme ... from double-stranded DNA (2), for selective ...
... DNA Ligation Kit enables ligation ... fragments in just 5 min ... on the DNA concentration, either ... concatemeric (high DNA concentration) ligation ...
Biology Products: